Objective:To systematically evaluate the efficacy and safety of Qianliexin capsule combined with western medicine in benign prostatic hyperplasia treatment.Methods:Randomized controlled trials of Qianliexin capsule co...Objective:To systematically evaluate the efficacy and safety of Qianliexin capsule combined with western medicine in benign prostatic hyperplasia treatment.Methods:Randomized controlled trials of Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia were searched from PubMed,the Cochrane Library,EMBASE,Web of Science,China National Knowledge Infrastructure,VIP,Wanfang and China Biomedical Literature Databases from establishment of the database to February 2021.Meta-analysis was performed using RevMan5.4 software after two researchers independently screened the literatures,extracted the data and evaluated the bias risks in the included studies according to the Cochrane Collaboration System Evaluator Manual.Results:6 randomized controlled trials involving 1060 patients were included.Meta-analysis results showed that the treatment group was better than the control group in total effective rate(Relative Risk=1.19,95%Confidence Interval(1.10,1.28),P<0.00001),International Prostate Symptom Score(Mean Difference=-2.99,95%confidence interval(-4.00,-1.99),P<0.00001),prostate volume(Mean Difference=-3.77,95%Confidence Interval(-4.67,-2.86),P<0.00001),postvoid residual urine volume(Mean Difference=-5.96,95%Confidence Interval(-8.15,-3.77),P<0.00001)and maximum urine flow rate(Mean Difference=3.45,95%Confidence Interval(2.53,4.37),P<0.00001).While there was no significant difference in the adverse effects rate(Relative Risk=0.71,95%Confidence Interval(0.33,1.56),P=0.40)between the treatment group and the control group.Conclusion:Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia showed good efficacy and high safety.However,more high-quality and large-sample studies are needed to confirm the above conclusions.展开更多
Background:To systematically evaluate the efficacy and safety of the Chinese patent medicine Shuxuening injection combined with western medicine in vascular dementia treatment.Methods:Randomized controlled trials of t...Background:To systematically evaluate the efficacy and safety of the Chinese patent medicine Shuxuening injection combined with western medicine in vascular dementia treatment.Methods:Randomized controlled trials of the Chinese patent medicine Shuxuening injection in vascular dementia treatment is searched in the databases of CNKI,Wanfang,VIP,CBM,PubMed,The Cochrane Library,Embase and Web of Science from the establishment time to December 2020.After screen the literature,extract the data and evaluate the bias risk of studies included;tRevMan5.3 was used for met-analysis.Results:Nine randomized controlled trials including 932 patients were included.The results of meta-analysis included:(1)the total effective rate(RR=1.27,95%CI(1.18,1.36),P<0.00001);(2)MMSE score(MD=4.78,95%CI(1.75,7.80),P=0.002);(3)ADL score(MD=8.87,95%CI(6.70,11.05),P<0.00001);(4)NIHSS score(MD=−6.60,95%CI(−7.04,−6.16).P<0.00001).The results of meta-analysis of the test group are better than those in the control group.Conclusion:The Chinese patent medicine Shuxuening injection combined with conventional western medicine has showed some advantages in the total effective rate,MMSE score,ADL score,NIHSS score than conventional western medicine without more side effects in vascular dementia treatment.More randomized,double-blind,large sample clinical studies are needed to confirm the above conclusions.展开更多
文摘Objective:To systematically evaluate the efficacy and safety of Qianliexin capsule combined with western medicine in benign prostatic hyperplasia treatment.Methods:Randomized controlled trials of Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia were searched from PubMed,the Cochrane Library,EMBASE,Web of Science,China National Knowledge Infrastructure,VIP,Wanfang and China Biomedical Literature Databases from establishment of the database to February 2021.Meta-analysis was performed using RevMan5.4 software after two researchers independently screened the literatures,extracted the data and evaluated the bias risks in the included studies according to the Cochrane Collaboration System Evaluator Manual.Results:6 randomized controlled trials involving 1060 patients were included.Meta-analysis results showed that the treatment group was better than the control group in total effective rate(Relative Risk=1.19,95%Confidence Interval(1.10,1.28),P<0.00001),International Prostate Symptom Score(Mean Difference=-2.99,95%confidence interval(-4.00,-1.99),P<0.00001),prostate volume(Mean Difference=-3.77,95%Confidence Interval(-4.67,-2.86),P<0.00001),postvoid residual urine volume(Mean Difference=-5.96,95%Confidence Interval(-8.15,-3.77),P<0.00001)and maximum urine flow rate(Mean Difference=3.45,95%Confidence Interval(2.53,4.37),P<0.00001).While there was no significant difference in the adverse effects rate(Relative Risk=0.71,95%Confidence Interval(0.33,1.56),P=0.40)between the treatment group and the control group.Conclusion:Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia showed good efficacy and high safety.However,more high-quality and large-sample studies are needed to confirm the above conclusions.
文摘Background:To systematically evaluate the efficacy and safety of the Chinese patent medicine Shuxuening injection combined with western medicine in vascular dementia treatment.Methods:Randomized controlled trials of the Chinese patent medicine Shuxuening injection in vascular dementia treatment is searched in the databases of CNKI,Wanfang,VIP,CBM,PubMed,The Cochrane Library,Embase and Web of Science from the establishment time to December 2020.After screen the literature,extract the data and evaluate the bias risk of studies included;tRevMan5.3 was used for met-analysis.Results:Nine randomized controlled trials including 932 patients were included.The results of meta-analysis included:(1)the total effective rate(RR=1.27,95%CI(1.18,1.36),P<0.00001);(2)MMSE score(MD=4.78,95%CI(1.75,7.80),P=0.002);(3)ADL score(MD=8.87,95%CI(6.70,11.05),P<0.00001);(4)NIHSS score(MD=−6.60,95%CI(−7.04,−6.16).P<0.00001).The results of meta-analysis of the test group are better than those in the control group.Conclusion:The Chinese patent medicine Shuxuening injection combined with conventional western medicine has showed some advantages in the total effective rate,MMSE score,ADL score,NIHSS score than conventional western medicine without more side effects in vascular dementia treatment.More randomized,double-blind,large sample clinical studies are needed to confirm the above conclusions.
